Latest Galderma Stories
In-demand research report “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” prepared by GlobalData is now available at MarketPublishers.com.
Expansion Completes Galderma's Global Skin Health Footprint FORT WORTH, Texas, July 10, 2014 /PRNewswire/ -- Galderma S.A.
LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.
-- Latest psychological research reveals rosacea redness creates negative first impressions putting sufferers at a disadvantage -- Rosacea remains under-diagnosed, yet diagnosis
LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.
ReportsnReports.com adds “OpportunityAnalyzer: Acne Vulgaris – Opportunity Analysis and Forecasts to 2018” to its store.
- Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in the U.S.
LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A.
Health Canada Approves The First and Only Topical Treatment Indicated for the Persistent Facial Erythema of Rosacea THORNHILL, ON, May 21, 2014 /CNW/ - Galderma Canada Inc.,
FORT WORTH, Texas, April 22, 2014 /PRNewswire/ -- The Cetaphil® brand of skin care products, manufactured by
- The act of lurking; skulking about; hiding; keeping from sight.